Together, we expand access to life-changing cancer care
alphaXRT joins EBOS MedTech in Australia and New Zealand.
EBOS MedTech continues to build a connected regional platform across Australia, New Zealand, Southeast Asia, Hong Kong and beyond, and today, that platform grows stronger.
We’re proud to welcome alphaXRT to the EBOS MedTech portfolio in Australia and New Zealand.
This acquisition brings together deep specialist expertise in radiation oncology with EBOS MedTech’s scale, reach and commitment to supporting healthcare professionals with education, service and local insight, all with one clear purpose: together, we can change lives.
Closing access gaps, supporting clinicians
As cancer incidence continues to rise across Australia and New Zealand, closing access gaps in radiotherapy remains critical for patients and their families. Despite advances in technology, utilisation across ANZ still trails optimal benchmarks, underscoring the need for stronger, more connected support for clinicians delivering complex cancer care.
“By welcoming alphaXRT into EBOS MedTech, we strengthen our ability to provide oncology clinicians with precision technology, world-leading education and dependable, on-the-ground service and support.”
It also enables clinicians to share best practise across APAC through offering regional professional education and networking with our clinicians across Southeast Asia and Hong Kong served by our broad oncology offering in Transmedic through its oncology presence in the region over the last 21 years.
A trusted leader in radiation oncology
alphaXRT is recognised as a leading independent supplier of radiation oncology solutions across ANZ, supporting treatment delivery, planning, medical physics and QA, and patient positioning. The business represents a portfolio of globally respected partners, including Accuray, RaySearch , Sun Nuclear/Mirion, TAE Lifesciences and MacroMedics enabling clinicians to treat confidently and efficiently.
“Joining EBOS MedTech, and the ability to collaborate with the LifeHealthcare team allows us to amplify what alphaXRT does best, deep technical expertise, strong clinical relationships and hands-on support, while extending our impact through a broader regional network. Together, we can help ensure advanced radiotherapy is accessible, reliable and delivered with confidence wherever patients need it.”
Richard Neale, Managing Director, alphaXRT
How this fits across LifeHealthcare and EBOS MedTech
Within ANZ, alphaXRT will work closely with LifeHealthcare, strengthening the oncology ecosystem through shared knowledge, education, and service capabilities. Across EBOS MedTech, together with LifeHealthcare, Transmedic and our wider portfolio, this acquisition deepens regional collaboration so innovation, education and support are shared consistently across borders.
The result: access to advanced care that isn’t defined by postcode, and a stronger, more connected platform for clinicians, partners and patients.
As EBOS MedTech continues to bring specialist businesses together, alphaXRT’s addition reflects our belief that scale matters most when it serves people, clinicians delivering care, and patients whose lives depend on it.
Follow our journey as the EBOS MedTech portfolio grows, explore alphaXRT and LifeHealthcare online.
Connect with us on LinkedIn.